



Sample **M. A**

Delta9 THC **ND**    THCa **ND**    Total THC (THC + THCa) **ND**    Delta8 THC **2.10%**

Sample ID SD230314-065 (68990)    Matrix Concentrate (Inhalable Cannabis Good)  
 Tested for Cabo Ella Group DBA Smilyn Wellness  
 Sampled -    Received Mar 14, 2023    Reported Mar 16, 2023  
 Analyses executed CANX

**CANX - Cannabinoids Analysis**

Analyzed Mar 16, 2023 | Instrument HPLC-VWD | Method SOP-001  
 The expanded Uncertainty of the Cannabinoid analysis is approximately  $\pm 8.06\%$  at the 95% Confidence Level

Analyte	LOD mg/g	LOQ mg/g	Result %	Result mg/g	Sample photography
11-Hydroxy- $\Delta^8$ -Tetrahydrocannabinol (11-Hyd- $\Delta^8$ -THCV)	0.013	0.041	ND	ND	
Cannabidiol (CBDO)	0.002	0.007	ND	ND	
Abnormal Cannabidiol (a-CBDO)	0.01	0.031	ND	ND	
(+/-)-9B-hydroxy-Hexahydrocannabinol (9b-HHC)	0.012	0.036	ND	ND	
11-Hydroxy- $\Delta^8$ -Tetrahydrocannabinol (11-Hyd- $\Delta^8$ -THC)	0.007	0.021	ND	ND	
Cannabidiolic Acid (CBDA)	0.001	0.16	ND	ND	
Cannabigerol Acid (CBGA)	0.001	0.16	ND	ND	
Cannabigerol (CBG)	0.001	0.16	ND	ND	
Cannabidiol (CBD)	0.001	0.16	ND	ND	
$\Delta^9$ (S)-THD (s-THD)	0.013	0.041	ND	ND	
$\Delta^9$ (R)-THD (r-THD)	0.025	0.075	ND	ND	
Tetrahydrocannabinol (THCV)	0.001	0.16	ND	ND	
$\Delta^8$ -tetrahydrocannabinol ( $\Delta^8$ -THCV)	0.021	0.064	ND	ND	
Cannabidiol (CBDH)	0.005	0.16	ND	ND	
Tetrahydrocannabinol ( $\Delta^9$ -THCB)	0.013	0.038	ND	ND	
Cannabinol (CBN)	0.001	0.16	ND	ND	
Cannabidiophorol (CBDP)	0.015	0.047	<b>14.82</b>	<b>148.24</b>	
exo-THC (exo-THC)	0.005	0.16	ND	ND	
Tetrahydrocannabinol ( $\Delta^9$ -THC)	0.003	0.16	ND	ND	
$\Delta^8$ -tetrahydrocannabinol ( $\Delta^8$ -THC)	0.004	0.16	<b>2.10</b>	<b>21.02</b>	
(6aR,9S)- $\Delta^{10}$ -Tetrahydrocannabinol ((6aR,9S)- $\Delta^{10}$ )	0.015	0.16	ND	ND	
Hexahydrocannabinol (S isomer) (9s-HHC)	0.017	0.16	ND	ND	
(6aR,9R)- $\Delta^{10}$ -Tetrahydrocannabinol ((6aR,9R)- $\Delta^{10}$ )	0.007	0.16	ND	ND	
Hexahydrocannabinol (R isomer) (9r-HHC)	0.016	0.16	ND	ND	
Tetrahydrocannabinolic Acid (THCA)	0.001	0.16	ND	ND	
$\Delta^9$ -Tetrahydrocannabinol ( $\Delta^9$ -THCH)	0.024	0.071	ND	ND	
Cannabinol Acetate (CBNO)	0.014	0.043	ND	ND	
$\Delta^9$ -Tetrahydrocannabinol ( $\Delta^9$ -THCP)	0.017	0.16	<b>45.85</b>	<b>458.50</b>	
$\Delta^8$ -Tetrahydrocannabinol ( $\Delta^8$ -THCP)	0.041	0.16	<b>3.45</b>	<b>34.46</b>	
Cannabicitran (CBT)	0.005	0.16	<b>11.06</b>	<b>110.58</b>	
$\Delta^8$ -THC-O-acetate ( $\Delta^8$ -THCO)	0.076	0.16	ND	ND	
9(S)-HHCP (s-HHCP)	0.031	0.094	ND	ND	
$\Delta^9$ -THC-O-acetate ( $\Delta^9$ -THCO)	0.066	0.16	ND	ND	
9(R)-HHCP (r-HHCP)	0.026	0.079	ND	ND	
9(S)-HHC-O-acetate (s-HHCO)	0.005	0.16	ND	ND	
3-octyl- $\Delta^8$ -Tetrahydrocannabinol ( $\Delta^8$ -THC-C8)	0.067	0.204	ND	ND	
$\Delta^9$ -THC methyl ether ( $\Delta^9$ -MeO-THC)			ND	ND	
<b>Total THC ( THCa * 0.877 + <math>\Delta^9</math>THC )</b>			ND	ND	
<b>Total THC + <math>\Delta^8</math>THC + <math>\Delta^{10}</math>THC ( THCa * 0.877 + <math>\Delta^9</math>THC + <math>\Delta^8</math>THC + <math>\Delta^{10}</math>THC )</b>			<b>2.10</b>	<b>21.02</b>	
<b>Total CBD ( CBDA * 0.877 + CBD )</b>			ND	ND	
<b>Total CBG ( CBGA * 0.877 + CBG )</b>			ND	ND	
<b>Total HHC ( 9r-HHC + 9s-HHC )</b>			ND	ND	
<b>Total Cannabinoids Analyzed</b>			<b>77.28</b>	<b>772.80</b>	

UJ Unidentified  
 ND Not Detected  
 N/A Not Applicable  
 NT Not Reported  
 LOD Limit of Detection  
 LOQ Limit of Quantification  
 <LOQ Detected  
 >ULOL Above upper limit of linearity  
 CFU/g Colony Forming Units per 1 gram  
 TNTC Too Numerous to Count



DCC license: C8-0000098-LIC  
 DEA license: RP0611043  
 ISO/IEC 17025:2017 Acc. L17-427-1



Scan the QR code to verify authenticity.

Authorized Signature

*Brandon Starr*

Brandon Starr, Lab Manager  
 Thu, 16 Mar 2023 13:11:35 -0700

PharmLabs San Diego | 3421 Hancock St, Second Floor, San Diego, CA 92110 | 619.356.0898 | ISO/IEC 17025:2017 Acc. L17-427-1



\*This report shall not be reproduced except in full, without the written approval of the lab. This report is for informational purposes only and should not be used to diagnose, treat or prevent any disease. Results are only for samples and batches indicated. Results are reported on an "as received" basis, unless indicated otherwise. When a Pass/Fail status is reported, that status is intended to be in accordance with federal, state and local laws which are required for the customer to be in compliance. The measurement of uncertainty is not included in the Pass/Fail evaluation unless explicitly required by federal, state or local laws and has been reported on the certificate of analysis. Measurement of uncertainty is available upon request.